Published in Circulation on July 28, 2003
Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol (2005) 5.30
Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med (2008) 2.68
Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des (2012) 1.42
Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure. Heart (2005) 1.26
Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des (2009) 1.09
Statin therapy lowers muscle sympathetic nerve activity and oxidative stress in patients with heart failure. Am J Physiol Heart Circ Physiol (2012) 1.01
Contribution of oxidative stress to pulmonary arterial hypertension. World J Cardiol (2010) 1.00
Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure. Heart (2006) 0.92
Redox Roles of Reactive Oxygen Species in Cardiovascular Diseases. Int J Mol Sci (2015) 0.91
Low doses of simvastatin therapy ameliorate cardiac inflammatory remodeling in Trypanosoma cruzi-infected dogs. Am J Trop Med Hyg (2011) 0.90
The effect of rosuvastatin in a murine model of influenza A infection. PLoS One (2012) 0.89
Vascular dysfunction in idiopathic dilated cardiomyopathy. Nat Rev Cardiol (2009) 0.89
Statin therapy blunts inflammatory activation and improves prognosis and left ventricular performance assessed by Tissue Doppler Imaging in subjects with chronic ischemic heart failure: results from the Daunia Heart Failure Registry. Clinics (Sao Paulo) (2011) 0.88
Effect of atorvastatin in patients with chronic heart failure - insights from randomized clinical trials. Arch Med Sci (2010) 0.88
Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases. Br J Clin Pharmacol (2008) 0.88
Statins in heart failure: do we need another trial? Vasc Health Risk Manag (2013) 0.88
Inhibition of mineralocorticoid receptor is a renoprotective effect of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor pitavastatin. J Hypertens (2011) 0.86
Statins in the treatment of chronic heart failure: a systematic review. PLoS Med (2006) 0.85
Statin therapy for cardiac hypertrophy and heart failure. J Investig Med (2004) 0.85
Statins in heart failure: the paradox between large randomized clinical trials and real life. Mayo Clin Proc (2012) 0.85
Lipophilic Statins and Aldosterone Secretion: A Bridge Too Far? Circulation (2015) 0.85
Atorvastatin therapy during the peri-infarct period attenuates left ventricular dysfunction and remodeling after myocardial infarction. PLoS One (2011) 0.84
Human cardiac fibroblasts express B-type natriuretic peptide: fluvastatin ameliorates its up-regulation by interleukin-1alpha, tumour necrosis factor-alpha and transforming growth factor-beta. J Cell Mol Med (2009) 0.84
Statins do not significantly affect muscle sympathetic nerve activity in humans with nonischemic heart failure: a double-blind placebo-controlled trial. J Card Fail (2011) 0.83
The "Statinth" wonder of the world: a panacea for all illnesses or a bubble about to burst. J Negat Results Biomed (2005) 0.82
The case for statin therapy in chronic heart failure. Clin Res Cardiol (2007) 0.81
Mitohormesis: another pleiotropic effect of statins? Eur Heart J (2011) 0.80
Utilisation of medications recommended for chronic heart failure and the relationship with annual hospitalisation duration in patients over 75 years of age. A pharmacoepidemiological study. Eur J Clin Pharmacol (2005) 0.79
Statins and the myocardium. Semin Vasc Med (2004) 0.79
The cornucopia of "pleiotropic" actions of statins: myogenesis as a new mechanism for statin-induced benefits? Circ Res (2009) 0.79
Spectrum of pleiotropic effects of statins in heart failure. Heart Fail Clin (2008) 0.78
Effects of statins on cardiorenal syndrome. Int J Vasc Med (2012) 0.78
Treatment with atorvastatin is associated with a better prognosis in chronic heart failure with systolic dysfunction: results from The Daunia Heart Failure Registry. Neth Heart J (2013) 0.78
Metabolic and immunologic derangements in cardiac cachexia: where to from here? Heart Fail Rev (2006) 0.78
Concomitant administration of different doses of simvastatin with ivabradine influence on PAI-1 and heart rate in normo- and hypercholesterolaemic rats. ScientificWorldJournal (2012) 0.77
Statin therapy decreases N-terminal pro-B-type natriuretic peptide in HIV: randomized placebo-controlled trial. AIDS (2015) 0.76
Short-term statin therapy and cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation (2004) 0.76
The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy--5-year follow-up. Lipids Health Dis (2013) 0.76
Reactive Oxygen Species: A Key Hallmark of Cardiovascular Disease. Adv Med (2016) 0.76
Should a statin be prescribed to every patient with heart failure? Heart Fail Rev (2007) 0.76
Heart failure: statins for all? Heart (2006) 0.75
Simvastatin ameliorates ventricular remodeling via the TGF‑β1 signaling pathway in rats following myocardial infarction. Mol Med Rep (2016) 0.75
No benefits of statins for sudden cardiac death prevention in patients with heart failure and reduced ejection fraction: A meta-analysis of randomized controlled trials. PLoS One (2017) 0.75
Statin Induced Regression of Cardiomyopathy Trial: A Randomized, Placebo-controlled Double-blind Trial. Heart Views (2017) 0.75
Pleiotropic effects of statins in the perioperative setting. Ann Card Anaesth (2017) 0.75
Effects of statin therapy on cardiac sympathetic nerve activity and left ventricular remodeling in patients with chronic heart failure: a propensity score-matched analysis. Medicine (Baltimore) (2014) 0.75
Remote ischaemic preconditioning does not alter perioperative cytokine production in high-risk cardiac surgery. Heart Asia (2012) 0.75
The effect of rosuvastatin on inflammation, matrix turnover and left ventricular remodeling in dilated cardiomyopathy: a randomized, controlled trial. PLoS One (2014) 0.75
Circulating Omentin-1 Levels Are Decreased in Dilated Cardiomyopathy Patients with Overt Heart Failure. Dis Markers (2016) 0.75
Left ventricular ejection fraction as therapeutic target: is it the ideal marker? Heart Fail Rev (2017) 0.75
Assessing cardiovascular risk in children with chronic kidney disease. B-type natriuretic peptide: a potential new marker. Pediatr Nephrol (2005) 0.75
Atorvastatin reduces β-Adrenergic dysfunction in rats with diabetic cardiomyopathy. PLoS One (2017) 0.75
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet (1994) 40.72
Regulation of the mevalonate pathway. Nature (1990) 18.25
Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet (1992) 11.50
Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med (1990) 5.65
Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA (2001) 5.54
Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol (1995) 5.26
Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation (1998) 5.11
Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest (2000) 4.79
The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med (1995) 3.60
Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med (1995) 3.32
Protein lipidation in cell signaling. Science (1995) 3.22
A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation (2000) 2.94
Congestive heart failure: fifty years of progress. Circulation (2000) 2.61
Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest (1998) 2.39
Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest (2001) 2.19
An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation (2001) 2.09
Neurohormonal interactions and adaptations in congestive heart failure. Circulation (1988) 1.98
Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation (1998) 1.96
HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol (1998) 1.91
Serum soluble heat shock protein 60 is elevated in subjects with atherosclerosis in a general population. Circulation (2000) 1.81
Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol (2001) 1.51
Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol (2000) 1.09
The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor beta. J Clin Invest (1995) 1.05
Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure? Circulation (1995) 1.00
Importance of endothelial function in chronic heart failure. J Cardiovasc Pharmacol (1996) 0.94
Increased levels of serum neopterin and decreased production of neutrophil superoxide anions in chronic heart failure with elevated levels of tumor necrosis factor-alpha. J Am Coll Cardiol (1993) 0.88
Abnormal neuroendocrine responses during exercise in heart transplant recipients. Circulation (1992) 0.87
The syndrome of heart failure: emerging concepts in the understanding of its pathogenesis and treatment. Curr Opin Cardiol (1999) 0.82
Evaluation of cardiac function by echo-Doppler studies in critically ill patients. Intensive Care Med (1988) 0.82
The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat Med (2007) 8.82
Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet (2002) 6.46
Involvement of endoplasmic reticulum stress in insulin resistance and diabetes. J Biol Chem (2004) 3.94
Increased endoplasmic reticulum stress in atherosclerotic plaques associated with acute coronary syndrome. Circulation (2007) 3.77
Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med (2002) 3.74
Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation (2008) 3.48
Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol (2004) 3.18
Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med (2002) 3.17
Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction: possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis. Circulation (2004) 3.16
FARP2 triggers signals for Sema3A-mediated axonal repulsion. Nat Neurosci (2005) 2.87
Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nat Med (2004) 2.82
Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med (2008) 2.68
Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol (2006) 2.61
Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke (2005) 2.56
AMP-activated protein kinase protects cardiomyocytes against hypoxic injury through attenuation of endoplasmic reticulum stress. Mol Cell Biol (2005) 2.56
Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. Circ Res (2002) 2.53
Involvement of nuclear factor-kappaB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation (2002) 2.50
Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proc Natl Acad Sci U S A (2003) 2.45
Impact of blockade of histamine H2 receptors on chronic heart failure revealed by retrospective and prospective randomized studies. J Am Coll Cardiol (2006) 2.44
Identification of a novel non-coding RNA, MIAT, that confers risk of myocardial infarction. J Hum Genet (2006) 2.41
Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation (2002) 2.39
Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol (2003) 2.39
Guidance of myocardial patterning in cardiac development by Sema6D reverse signalling. Nat Cell Biol (2004) 2.39
Essential role of endothelial Notch1 in angiogenesis. Circulation (2005) 2.28
Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. Proc Natl Acad Sci U S A (2002) 2.27
Dual roles of Sema6D in cardiac morphogenesis through region-specific association of its receptor, Plexin-A1, with off-track and vascular endothelial growth factor receptor type 2. Genes Dev (2004) 2.22
Rho GTPases, statins, and nitric oxide. Circ Res (2005) 2.21
Low levels of serum n-3 polyunsaturated fatty acids are associated with worse heart failure-free survival in patients after acute myocardial infarction. Circ J (2012) 2.15
UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther (2004) 2.14
Pleiotropic effects of statins. - Basic research and clinical perspectives -. Circ J (2010) 2.13
Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke (2005) 2.13
Endoplasmic reticulum stress as a therapeutic target in cardiovascular disease. Circ Res (2010) 2.12
Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1+/- haploinsufficient mice. Circulation (2005) 2.09
Overexpression of endoplasmic reticulum-resident chaperone attenuates cardiomyocyte death induced by proteasome inhibition. Cardiovasc Res (2008) 2.05
Ventricular septal defect and cardiomyopathy in mice lacking the transcription factor CHF1/Hey2. Proc Natl Acad Sci U S A (2002) 2.04
Regulation of endothelial nitric oxide synthase and postnatal angiogenesis by Rac1. Circ Res (2008) 2.04
Requirement of Rac1 in the development of cardiac hypertrophy. Proc Natl Acad Sci U S A (2006) 2.02
Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One (2011) 2.01
Modulation of the JNK pathway in liver affects insulin resistance status. J Biol Chem (2004) 1.99
Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation (2009) 1.95
p38alpha mitogen-activated protein kinase plays a critical role in cardiomyocyte survival but not in cardiac hypertrophic growth in response to pressure overload. Mol Cell Biol (2004) 1.95
Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol (2003) 1.95
ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. J Clin Invest (2008) 1.92
Critical role of endothelial Notch1 signaling in postnatal angiogenesis. Circ Res (2006) 1.91
Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch Biochem Biophys (2005) 1.91
The forkhead transcription factor Foxo1 bridges the JNK pathway and the transcription factor PDX-1 through its intracellular translocation. J Biol Chem (2005) 1.87
Influence of serotonin transporter gene polymorphism on depressive symptoms and new cardiac events after acute myocardial infarction. Am Heart J (2005) 1.86
ER stress in cardiovascular disease. J Mol Cell Cardiol (2009) 1.85
Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circ Res (2006) 1.84
Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc Res (2005) 1.84
Activation of adenosine A1 receptor attenuates cardiac hypertrophy and prevents heart failure in murine left ventricular pressure-overload model. Circ Res (2003) 1.82
Rapid nongenomic actions of thyroid hormone. Proc Natl Acad Sci U S A (2006) 1.79
Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation (2004) 1.79
Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. J Clin Invest (2004) 1.79
NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. J Mol Cell Cardiol (2003) 1.75
Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. Mol Cell Biol (2003) 1.75
Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol (2006) 1.74
Statistical image analysis of cerebral blood flow in vascular dementia with small-vessel disease. J Nucl Med (2003) 1.73
A functional SNP in PSMA6 confers risk of myocardial infarction in the Japanese population. Nat Genet (2006) 1.73
Targeted deletion of apoptosis signal-regulating kinase 1 attenuates left ventricular remodeling. Proc Natl Acad Sci U S A (2003) 1.73
Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and translational aspects of protective measures. Am J Physiol Heart Circ Physiol (2011) 1.73
Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation (2004) 1.73
AMPK controls the speed of microtubule polymerization and directional cell migration through CLIP-170 phosphorylation. Nat Cell Biol (2010) 1.72
Prolonged targeting of ischemic/reperfused myocardium by liposomal adenosine augments cardioprotection in rats. J Am Coll Cardiol (2009) 1.71
Inhibition of autophagy in the heart induces age-related cardiomyopathy. Autophagy (2010) 1.70
Failure to prevent progressive dilation of ascending aorta by aortic valve replacement in patients with bicuspid aortic valve: comparison with tricuspid aortic valve. Circulation (2003) 1.69
Ca(2+)-sensitive tyrosine kinase Pyk2/CAK beta-dependent signaling is essential for G-protein-coupled receptor agonist-induced hypertrophy. J Mol Cell Cardiol (2004) 1.68
PDX-1/VP16 fusion protein, together with NeuroD or Ngn3, markedly induces insulin gene transcription and ameliorates glucose tolerance. Diabetes (2005) 1.68
Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-alpha secretion in vitro. Nature (2004) 1.68
RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis. FASEB J (2010) 1.67
Long-term statin use and psychological well-being. J Am Coll Cardiol (2003) 1.66
Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol (2009) 1.63
FHL2/SLIM3 decreases cardiomyocyte survival by inhibitory interaction with sphingosine kinase-1. Circ Res (2006) 1.63
Ablation of C/EBP homologous protein attenuates endoplasmic reticulum-mediated apoptosis and cardiac dysfunction induced by pressure overload. Circulation (2010) 1.63
Cardiac-specific overexpression of sarcolipin inhibits sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA2a) activity and impairs cardiac function in mice. Proc Natl Acad Sci U S A (2004) 1.63
Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol (2010) 1.62
A cardiac myosin light chain kinase regulates sarcomere assembly in the vertebrate heart. J Clin Invest (2007) 1.61
Reduced collateral circulation to the infarct-related artery in elderly patients with acute myocardial infarction. J Am Coll Cardiol (2004) 1.61
Targeting eNOS for stroke protection. Trends Neurosci (2004) 1.60
Preservation of NO production by statins in the treatment of heart failure. Cardiovasc Res (2003) 1.59
Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts. Cardiovasc Drugs Ther (2005) 1.59